Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671632 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12634565 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17325408 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12634582 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL24467522 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL738 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21470181 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL14980248 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025551-A1 | COMPOSITIONS AND METHODS FOR INDUCING AND ENHANCING AN IMMUNE RESPONSE | UNIV MICHIGAN STATE (US) | 2025-01-23 | — | — | US | claimed |
| WO-2024201004-A1 | COMBINATORIAL IL-15 THERAPY | Prostate Cancer Research (GB) | 2024-10-03 | — | — | WO | claimed |
| US-20220211842-A1 | Methods and Devices for the Treatment of Food Allergies | TEXAS TECH UNIVERSITY SYSTEM | 2022-07-07 | — | — | US | claimed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| US-12629414-B2 | Methods and devices for the treatment of food allergies | TEXAS TECH UNIVERSITY SYSTEM (US) | 2026-05-19 | — | — | US | disclosed |
| US-12616712-B2 | Sting agonist comprising exosomes for treating neuroimmunological disorders | LONZA SALES AG (CH) | 2026-05-05 | — | — | US | disclosed |
| EP-4725557-A2 | METHODS AND DEVICES FOR THE TREATMENT OF FOOD ALLERGIES | Texas Tech University System (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3630175-B1 | METHODS AND DEVICES FOR THE TREATMENT OF FOOD ALLERGIES | UNIV TEXAS TECH SYSTEM (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705451-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | Lonza Sales AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4695405-A2 | SMALL-MOLECULE REGULATED ALTERNATIVE SPLICING | Rgenta Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | LONZA SALES AG (CH) | 2026-02-12 | — | — | US | disclosed |
| WO-2022066928-A2 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | CODIAK BIOSCIENCES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-114080232-A | Extracellular vesicles for vaccine delivery | 科迪亚克生物科学公司 | 2022-02-22 | — | — | CN | disclosed |
| WO-2022036159-A2 | IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS | Actym Therapeutics, Inc. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11242521-B2 | Obtainment of a rough-type Salmonella enteritidis and its genetic modifications for use as an avian vaccine | FARMACOLOGICOS VETERINARIOS S.A.C.—FARVET | 2022-02-08 | — | — | US | disclosed |
| EP-3941607-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | Codiak BioSciences, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941937-A2 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | Codiak BioSciences, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-10787479-B2 | Crystalline 3′,5′-cyclic diguanylic acid | YAMASA CORPORATION (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20190315795-A1 | CRYSTALLINE 3',5'-CYCLIC DIGUANYLIC ACID | YAMASA CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20170101432-A1 | CRYSTALLINE 3',5'-CYCLIC DIGUANYLIC ACID | YAMASA CORPORATION (JP) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | EXOSC10, EXOSC5, HLA-DRB1 | STING1 109/4885PDE3B 2634/4885PDE3A 2978/4885 |
| US-10787479-B2 | Crystalline 3′,5′-cyclic diguanylic acid | NT5C3B, GDA, GANC | STING1 1787/4885PDE3B 260/4885PDE3A 103/4885 |
| US-12616712-B2 | Sting agonist comprising exosomes for treating neuroimmunological disorders | STING1, TMIGD3, PLA2G4B | STING1 1/4885PDE3B 1404/4885PDE3A 1232/4885 |
| US-20170101432-A1 | CRYSTALLINE 3',5'-CYCLIC DIGUANYLIC ACID | GDA, NT5C3B, CA3 | STING1 1708/4885PDE3B 241/4885PDE3A 90/4885 |
| US-20190315795-A1 | CRYSTALLINE 3',5'-CYCLIC DIGUANYLIC ACID | GDA, NT5C3B, CA3 | STING1 1708/4885PDE3B 241/4885PDE3A 90/4885 |
| US-12629414-B2 | Methods and devices for the treatment of food allergies | CUTA, CD69, TSLP | STING1 2560/4885PDE3B 4645/4885PDE3A 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.